Cordlife Group Limited (SGX: P8A)

Market Cap	40.50M
Revenue (ttm)	36.61M
Net Income (ttm)	-11.06M
Shares Out	256.31M
EPS (ttm)	-0.04
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	30,400
Open	0.158
Previous Close	0.156
Day's Range	0.158 - 0.158
52-Week Range	0.118 - 0.455
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 8, 2024

About Cordlife Group

Cordlife Group Limited, an investment holding company, provides cord blood banking services in Singapore, Hong Kong, India, Malaysia, the Philippines, and internationally. The company operates through two segments, Banking and Diagnostics. It offers cord blood, cord lining, and cord tissue banking services, including processing and storage of stem cells; and various diagnostics services, such as newborn genetic screening, pediatric vision and ear screening, pediatric allergen test, genetic talent test, preimplantation genetic screening, endomet...

• Industry: Miscellaneous Health And Allied Services, Not Elsewhere Classified
• Founded: 2001
• Employees: 538
• Stock Exchange: Singapore Exchange
• Ticker Symbol: P8A

Financial Performance

In 2023, Cordlife Group's revenue was 55.73 million, an increase of 1.04% compared to the previous year's 55.16 million. Earnings were 3.52 million, a decrease of -27.91%.